Volume 27, supplement 4, Novembre 2020

ÉDITORIAL

But where are we going to stop? (p.5-7)
Laurent Peyrin-Biroulet

MINI-REVUES

Unmet needs in Ulcerative Colitis (p.8-13)
Pauline Rivière, David Laharie

New molecules (excluding JAK-STAT): What interests for patients in the future? (p.14-9)
Arnaud Bourreille

New therapeutic objectives in Inflammatory Bowel Disease – Histological remission in ulcerative colitis and Crohn's disease (p.20-6)
Benjamin Pariente, Pauline Wils

Can we predict primary non-response to biotherapy in Inflammatory Bowel Disease? (p.27-32)
Xavier Roblin, Stéphane Paul

Input of combination therapy in the management of Inflammatory Bowel Disease and for which benefit/risk ratio? (p.33-42)
Camille Meunier, Claire Gay, Gilles Boschetti, Chloé Venturin, Mathias Faure, Bernard Flourié, Stéphane Nancey

Selective and non-selective JAK-STAT in Inflammatory Bowel Disease (p.43-51)
Mathieu Uzzan, Yoram Bouhnik